Список проголосовавших за комментарий " Regulus Therapeutics downgraded to Hold at Needham — HCV program concerns persist (2.25)Needham downgrades RGLS to Hold from Buy after co announced late Friday that FDA has extended RG-101 clinical hold and requested additional long-term clinical data from ongoing trials. These data are not expected until 4Q17. Firm has removed the program from our model considering extensive development risk. Regardless, opportunity for RGLS to capture value in HCV is fading in our view given growing number of effective oncedaily oral options. <strong>Though they believe microRNA platform has substantial potential, firm downgrades to HOLD due to absence of near-term material clinical milestones.</strong> A key value-creating milestone in their view is top-line results from Phase 2 proof-ofconcept trial of RG-012 in Alport Syndrome. This trial is expected to begin mid-2017, with results available in 2018. Data from RG-125 Phase 2 trial in NAFLD (collaborator AstraZeneca) are expected 3Q17."